Recent investigations suggest that Adenosine Deaminase (ADA) could play a role in susceptibility to rheumatoid arthritis (RA). The purpose of our study is to investigate the possible role of genetic variability of ADA in the susceptibility to RA. We studied three intragenic ADA polymorphisms, ADA., ADA z andADA 6 , in a sample of91 subjects with RAand in 246 healthy subjects from the same Caucasian population and compared genotype and pairwise haplotype distributions between cases and controls. No statistically significant differences between RA and controls are observed for ADA genotypes. A border line difference for ADA.-ADA z haplotype distribution is observed due to a decreased proportion of ADA/2/ADAz*2 haplotype in RA compared to controls. Our data indicate a border line effect of ADA gene polymorphism on susceptibility to RA that need to be confirmed in other clinical settings.
Alterations in Adenosine Deaminase (ADA) activity in serum, peripheral blood lymphocytes and synovial fluid have been reported with Rheumatoid Arthritis (RA) (1) (2) , suggesting that ADA could playa role in the susceptibility and/or in the clinical variability of the disease. Moreover, recent studies point to an important role of adenosine concentration on local inflammation in RA (3) . A specific increase in enzymatic activity of ADA in rheumatoid synovial fibroblasts has been observed, suggesting that elevated ADA activity may contribute to the pathogenesis of RA through a neutralization of antirheumatic properties of endogenous adenosine (2) . Many anti-inflammatory effects of methotrexate are mediated by adenosine and it has been shown that ADA contributes significantly to the interindividual variations to methotrexate response among patients with rheumatoid arthritis (4) (5) .
In the present paper we studied three intragenic adenosine deaminase polymorphisms (PCRPs) in a sample of adult subjects with RA. The three PCRPs spanning over approximately 28 Kb have a known molecular basis and include the presence/absence of a TaqI site (ADAI) (nt 4050-4053, exon I), of a PstI site (ADA2) (nt 19465-19470, intron 2) and a MluNI site'(ADA6) (nt 31230-31235, exon 6) (6). Only the TaqI PCRP at exon I corresponds to a functional variation, as the G>A transition at nt 4052 results both in the loss of a TaqI site (TCGA/TCAA) and in the substitution of asparagine for aspartic acid at codon 8 (7) . The Asp8Asn mutation is the molecular genetic basis for the common biochemical polymorphism at the ADA locus reported by Spencer et al. (8) with two common alleles ADA *1 and ADA*2.
MATERIALS AND METHODS
Ninety-one subjects (67 females and 24 males) with a diagnosis of rheumatoid arthritis, according to ACR criteria, were studied in the Caucasian population of Rome. Mean age was 60 (S.D. 3.42). Median age at onset was 54.5 years (S.D. 16.5).
Two hundred and forty-six healthy subjects (blood donors) from the same Caucasian population were also studied. The Institutional Review Board approved the investigation and informed consent was obtained from all subjects.
ADA genotypes were determined by PCR. Genomic DNA was extracted from venous blood samples collected in NaEDTA using a procedure described by Kunkel (9) with slight modifications. PCR amplification was carried out as described by Hirschhorn et al. (7) with slight modifications. Briefly, the PCR volume was 25 III containing 100 ng of DNA, 1.5 mM MgCI 2 , 2.5x reaction buffer, 5 pmoles of each primer, 50 mM each dNTP, 2 U of Supertherm DNA polymerase (LPI FISHER). Thirty cycles (I min at 95°C, I min and 30 sec at 65°C, 2 min at n°C) were performed using a DNA Thermal Cycler (Perkin Elmer).
Sense and antisense primers for 4052 Taql polymorphism (ADA I) were respectively: 5' -ACCGAGCCGGCAGAGACCCAC-3' 5' -ACTTGAC AGACAGCGAAACTGAGACCCAGA-
3'
Sense and antisense primers tor 19465 Pstl polymorphism (ADA2) were respectively: 5' -GAGCACAAGCTTTGGAATTGGGCTTGGGTT-3' 5'-ACACCAGGAGGACAAGACTCAGAGGCCCAG AA-3' Sense and antisense primers for 31230 MluNI polymorphism (ADA6) were respectively:
7 I.tI of each reaction was digested in 2 U of the specific enzyme according to the manufacturer's directions. Each digestion was resolved on 3% agarose gel in TAE (Tris! acetate!EDTA) buffer pH 8.0. Following electrophoresis, the gel was stained with ethidium bromide and the fragments were visualized by Ll.V.
The alleles corresponding to the presence and absence of the restriction sites have been signed as allele I and allele 2 respectively. Determination of genotypes were made in groups of twenty including cases and controls in order to eliminate possible errors due to incomplete enzymatic digestion.
Haplotype frequencies are maximum likelihood estimates (MENDEL program, Dept. of Biostatistics, University of Michigan, Ann Harbour, MI, USA). The measure of linkage disequilibrium (i.e. the D parameter) was calculated as the product of the frequencies of the genotypes in coupling divided by the product of the frequencies of the genotypes in repulsion. Statistical analyses were performed using the SPSS package. Genotype distributions do not show significant differences from the Hardy-Weinberg expectations. Table I shows the distribution ofADA genotypes in RA and Controls. No significant difference is observed between RA and controls. Table II shows the pairwise haplotype distribution in RA and Controls. In the controls there is strong disequilibrium in ADA ,-ADA 2 haplotypic class that is reduced in RA.
RESULTS
Comparing RA with controls it appears that there is a relative decrease ofADA! *2!ADA 2 *2 haplotype in RA (p-0,05 OR=0,32) as compared to controls, thus drastically reducing the value of disequilibrium in RA. No significant difference is observed for ADA 1-ADA6 and ADA 2-ADA6 haplotypes between RA and controls.
DISCUSSION
Genetic factors play a relevant role In autoimmunity. It has been suggested that besides major histocompatibility complex (MHC)-linked candidate gene there are also non-MHC-linked candidate genes involved in autoimmunity. Moreover, there could be unique genes for a given disease determining susceptibility of a target organ to an autoimmune attack (10) .
Adenosine Deaminase (ADA) is a polymorphic enzyme that irreversibly deaminates adenosine to inosine thus contributing to the regulation of intracellular and extracellular concentration of adenosine. Subjects homozygous for a rare silent allele of ADA may experience severe combined immunodeficiency (SCID)i It has been proposed that inhibition of ADA( activity reduces DNA synthesis through raised intr~cellular adenosine concentration, which causes an accumulation of toxic derivatives. The lack of nucleic acid synthesis would cause lymphopenia in patients with SCID. More recently it has been shown that ADA is present on the surface of many cell types including lymphocytes where it may function as an ecto-enzyme contributing to development and functionality of lymphoid tissue (II). The ADA structural gene is localized on human chromosome 20q 13.11 and consists of 12 exons spanning approximately 32Kb of DNA (12) . A high number of differences among normal sequences have been found through the coding and intronic regions of the gene (6) . It is unknown at present if such ADA genetic variability affects its enzymatic activity and/or its interaction with ADA binding proteins (ADABP) but ADA seems a good candidate gene for the susceptibility to common immune-mediated diseases.
Adenosine regulates glucose metabolism and immunological functions. High ADA activity could be associated to low concentration of adenosine resulting in low activity of adenosine receptors and in turn to a weakening of T cell activation and increased glucose tolerance. On the contrary, low ADA activity would be associated to high adenosine concentration resulting in high activity of adenosine receptors and in turn to strengthening of T cell activation and increased glucose tolerance. The severe consequences ofADA deficit due the presence of ADA o allele are well-known. Less investigated are the possible consequences at clinical level of the "normal" genetic variability of ADA activity due to genetic polymorphism.
ADA was supposed to be an exclusively cytosolic enzyme until the recent demonstration that it is present on the surface of erythrocyte and platelets. Subsequently, it has been demonstrated that ADA is present on the surface of many cell types including lymphocytes where it can act as an ectoenzyme (II). The functional role of ecto-ADA is related but not limited to the local degradation of extracellular adenosine as ecto-ADA is also able to transduce signals through its interaction with CD26 or AIR, two ADA anchoring proteins. In this way it acts as a costimulatory molecule, which facilitates a variety of specific signalling events in different cell types (11) . Quantitatively, the strength of the signal would depend upon the concentration of ecto-ADA available. ADA biochemical polymorphism could contribute to modulate ecto-ADA function and consequently the development and functionality of lymphoid tissue. Haplotypes involving ADA) and ADA 2 loci show a border line significant association with RA. This might suggest that in the area between ADA j and ADA 2 a sequence could be located which plays a role in the susceptibility to RA. However, in view of the relatively small size of the sample examined, the present study has to be considered as a preliminary approach that needs to be confirmed in other population.
Our data seem to indicate a modest effect ofgenetic variability of ADA gene on the susceptibility to RA. Recent data (5), however, suggest an involvement of ADA polymorphism in the clinical variability of RA response to treatment with methotrexate pointing to an important role of the enzyme in this disease and opening new interesting perspectives of research.
